NTEC News and Press, Intec Pharma Ltd. From 09/18/19

The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...

September 16, 2019 Palm Beach, FL –September 16, 2019 – The global cancer therapy market looks like it will continue trend to continue its growth… worldwide. Cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with spec...

JERUSALEM , Sept. 16, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented a...

JERUSALEM , Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September. HC Wainwright 21 st Annual Global Investment Confere...

Nano cap Intec Pharma ( NTEC +42.3% ) is up on more than a 12x surge in volume. Investors are apparently excited that CEO Jeffrey Meckler and board member John Kozarich purchased a total of 200K shares according to insider buying data provider The Washington Service . More news on: Inte...

Intec Pharma (NASDAQ: NTEC ): Q2 GAAP EPS of -$0.30 in-line. More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

JERUSALEM , Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and six months ended June 30 , 2019.   Highlights of the second quarter 2019 and recent weeks include: Comple...

Introduction On Monday, Intec Pharma ( NTEC ) announced their phase 3 trial assessing their proprietary Accordion Pill-Carbidopa/Levodopa for Parkinson's disease did not prove superior to immediate-release Carbidopa/Levodopa (Sinemet). We are disappointed that the ACCORDANCE stud...

Intec Pharma (NASDAQ: NTEC )  -82%  after Accordion Pill flunks late-stage Parkinson's study More news on: Intec Pharma Ltd., Neuralstem, Inc., Midatech Pharma Plc, Stocks on the move, Read more ...

JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill ® -Carbidopa/Levodopa (AP...